531 related articles for article (PubMed ID: 19273530)
1. Metabolic disposition of [14C]bazedoxifene in healthy postmenopausal women.
Chandrasekaran A; McKeand WE; Sullivan P; DeMaio W; Stoltz R; Scatina J
Drug Metab Dispos; 2009 Jun; 37(6):1219-25. PubMed ID: 19273530
[TBL] [Abstract][Full Text] [Related]
2. Absorption, metabolism, and excretion of [14C]imidafenacin, a new compound for treatment of overactive bladder, after oral administration to healthy male subjects.
Ohmori S; Miura M; Toriumi C; Satoh Y; Ooie T
Drug Metab Dispos; 2007 Sep; 35(9):1624-33. PubMed ID: 17567733
[TBL] [Abstract][Full Text] [Related]
3. Metabolism and disposition of a potent and selective GABA-Aalpha2/3 receptor agonist in healthy male volunteers.
Polsky-Fisher SL; Vickers S; Cui D; Subramanian R; Arison BH; Agrawal NG; Goel TV; Vessey LK; Murphy MG; Lasseter KC; Simpson RC; Vega JM; Rodrigues AD
Drug Metab Dispos; 2006 Jun; 34(6):1004-11. PubMed ID: 16510541
[TBL] [Abstract][Full Text] [Related]
4. Metabolism and excretion of [(14)C]celecoxib in healthy male volunteers.
Paulson SK; Hribar JD; Liu NW; Hajdu E; Bible RH; Piergies A; Karim A
Drug Metab Dispos; 2000 Mar; 28(3):308-14. PubMed ID: 10681375
[TBL] [Abstract][Full Text] [Related]
5. Disposition and metabolism of 14C-rifapentine in healthy volunteers.
Reith K; Keung A; Toren PC; Cheng L; Eller MG; Weir SJ
Drug Metab Dispos; 1998 Aug; 26(8):732-8. PubMed ID: 9698286
[TBL] [Abstract][Full Text] [Related]
6. Absorption, metabolism, and excretion of [(14)C]MK-0524, a prostaglandin D(2) receptor antagonist, in humans.
Karanam B; Madeira M; Bradley S; Wenning L; Desai R; Soli E; Schenk D; Jones A; Dean B; Doss G; Garrett G; Crumley T; Nirula A; Lai E
Drug Metab Dispos; 2007 Jul; 35(7):1196-202. PubMed ID: 17431030
[TBL] [Abstract][Full Text] [Related]
7. Glucuronidation as a major metabolic clearance pathway of 14c-labeled muraglitazar in humans: metabolic profiles in subjects with or without bile collection.
Wang L; Zhang D; Swaminathan A; Xue Y; Cheng PT; Wu S; Mosqueda-Garcia R; Aurang C; Everett DW; Humphreys WG
Drug Metab Dispos; 2006 Mar; 34(3):427-39. PubMed ID: 16381667
[TBL] [Abstract][Full Text] [Related]
8. Disposition and metabolism of radiolabeled casopitant in humans.
Pellegatti M; Bordini E; Fizzotti P; Roberts A; Johnson BM
Drug Metab Dispos; 2009 Aug; 37(8):1635-45. PubMed ID: 19420128
[TBL] [Abstract][Full Text] [Related]
9. Disposition of bazedoxifene in rats.
Chandrasekaran A; Ahmad S; Shen L; DeMaio W; Hultin T; Scatina J
Xenobiotica; 2010 Aug; 40(8):578-85. PubMed ID: 20528166
[TBL] [Abstract][Full Text] [Related]
10. Disposition of [14C]ruboxistaurin in humans.
Burkey JL; Campanale KM; Barbuch R; O'Bannon D; Rash J; Benson C; Small D
Drug Metab Dispos; 2006 Nov; 34(11):1909-17. PubMed ID: 16896067
[TBL] [Abstract][Full Text] [Related]
11. Metabolism and excretion of a novel antianxiety drug candidate, CP-93,393, in Long Evans rats. Differentiation of regioisomeric glucuronides by LC/MS/MS.
Prakash C; Soliman V
Drug Metab Dispos; 1997 Nov; 25(11):1288-97. PubMed ID: 9351906
[TBL] [Abstract][Full Text] [Related]
12. The absorption, metabolism, and excretion of the novel neuromodulator RWJ-333369 (1,2-ethanediol, [1-2-chlorophenyl]-, 2-carbamate, [S]-) in humans.
Mannens GS; Hendrickx J; Janssen CG; Chien S; Van Hoof B; Verhaeghe T; Kao M; Kelley MF; Goris I; Bockx M; Verreet B; Bialer M; Meuldermans W
Drug Metab Dispos; 2007 Apr; 35(4):554-65. PubMed ID: 16936066
[TBL] [Abstract][Full Text] [Related]
13. Absorption, metabolism, and excretion of [14C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans.
He H; Tran P; Yin H; Smith H; Batard Y; Wang L; Einolf H; Gu H; Mangold JB; Fischer V; Howard D
Drug Metab Dispos; 2009 Mar; 37(3):536-44. PubMed ID: 19074975
[TBL] [Abstract][Full Text] [Related]
14. Disposition and metabolism of [14C]SB-649868, an orexin 1 and 2 receptor antagonist, in humans.
Renzulli C; Nash M; Wright M; Thomas S; Zamuner S; Pellegatti M; Bettica P; Boyle G
Drug Metab Dispos; 2011 Feb; 39(2):215-27. PubMed ID: 21045199
[TBL] [Abstract][Full Text] [Related]
15. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme.
Kassahun K; McIntosh I; Cui D; Hreniuk D; Merschman S; Lasseter K; Azrolan N; Iwamoto M; Wagner JA; Wenning LA
Drug Metab Dispos; 2007 Sep; 35(9):1657-63. PubMed ID: 17591678
[TBL] [Abstract][Full Text] [Related]
16. The disposition and metabolism of [14C]fluconazole in humans.
Brammer KW; Coakley AJ; Jezequel SG; Tarbit MH
Drug Metab Dispos; 1991; 19(4):764-7. PubMed ID: 1680653
[TBL] [Abstract][Full Text] [Related]
17. Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling.
Zhang D; Wang L; Raghavan N; Zhang H; Li W; Cheng PT; Yao M; Zhang L; Zhu M; Bonacorsi S; Yeola S; Mitroka J; Hariharan N; Hosagrahara V; Chandrasena G; Shyu WC; Humphreys WG
Drug Metab Dispos; 2007 Jan; 35(1):150-67. PubMed ID: 17062777
[TBL] [Abstract][Full Text] [Related]
18. Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans.
Prakash C; Kamel A; Gummerus J; Wilner K
Drug Metab Dispos; 1997 Jul; 25(7):863-72. PubMed ID: 9224781
[TBL] [Abstract][Full Text] [Related]
19. Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers.
Takusagawa S; van Lier JJ; Suzuki K; Nagata M; Meijer J; Krauwinkel W; Schaddelee M; Sekiguchi M; Miyashita A; Iwatsubo T; van Gelderen M; Usui T
Drug Metab Dispos; 2012 Apr; 40(4):815-24. PubMed ID: 22269146
[TBL] [Abstract][Full Text] [Related]
20. The metabolic disposition of aprepitant, a substance P receptor antagonist, in rats and dogs.
Huskey SE; Dean BJ; Doss GA; Wang Z; Hop CE; Anari R; Finke PE; Robichaud AJ; Zhang M; Wang B; Strauss JR; Cunningham PK; Feeney WP; Franklin RB; Baillie TA; Chiu SH
Drug Metab Dispos; 2004 Feb; 32(2):246-58. PubMed ID: 14744948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
